Effect of Efavirenz on Endogenous Progesterone Concentrations and Contraceptive Outcomes among Ugandan HIV Infected Women Coadministering Ethinylestradiol/Levonorgestrel.
Effect of Efavirenz on Endogenous Progesterone Concentrations and Contraceptive Outcomes among Ugandan HIV Infected Women Coadministering Ethinylestradiol/Levonorgestrel.
复制标题
依非韦伦对联合使用炔雌醇/左炔诺孕酮的乌干达 HIV 感染妇女内源性黄体酮浓度和避孕结果的影响。
DOI：
10.1155/2017/6531709
复制
发表时间：
2017
影响因子：
1.7
通讯作者：
Nanzigu,Sarah
中科院分区：
文献类型：
--
作者：
Munkwase,Grant;Bisaso,KuteesaR;Kakaire,Othman;Nanzigu,Sarah
本研究评估了 49 名同时服用炔雌醇/左炔诺孕酮的 HIV 感染女性中依非韦伦中等剂量血浆浓度对黄体中部内源性黄体酮浓度和避孕结果的影响，其中包括 34 名接受高效抗逆转录病毒治疗 (HAART) 的 HIV 阳性女性和 15 名从未接受过 HAART 的 HIV 感染女性，这些女性特意选自 Mulago 医院， 乌干达。在每位女性月经周期的第 20 天至 22 天之间采集一次血样，分别通过电化学发光技术和高效液相色谱 (HPLC) 测量内源性黄体酮和依非韦伦浓度。使用 SPSS v.21 和 R3.1 进行描述性统计分析以及相关性和逻辑回归分析。当依非韦伦浓度低于 12μg/ml 时，依非韦伦与内源性黄体酮呈弱正线性关系。根据血清内源性孕酮，观察到的激素避孕失败率（24.5%）高于预期（最高8%）。接受基于依非韦伦的 HAART 治疗的 HIV 阳性女性 (26.5%) 面临避孕失败风险的比例高于未接受过 HAART 治疗的 HIV 感染者 (20%)，尽管这在统计上并不显着 (p= 0.63)。在同时服用炔雌醇/左炔诺孕酮口服药的艾滋病毒感染乌干达妇女中，依非韦伦中剂量血浆浓度似乎对黄体中期内源性黄体酮浓度和避孕结果没有显着影响。
This study assessed the effect of efavirenz mid‐dose plasma concentrations on mid‐luteal endogenous progesterone concentrations and contraceptive outcomes among 49 HIV infected women coadministering ethinylestradiol/levonorgestrel, including 34 HIV positive women on Highly Active Antiretroviral Therapy (HAART) and 15 HAART naïve HIV infected women, purposively selected from Mulago Hospital, Uganda. A blood sample was collected once between days 20 and 22 of each woman’s menstrual cycle for measuring endogenous progesterone and efavirenz concentrations by electrochemiluminescence technology and High Performance Liquid Chromatography (HPLC), respectively. Descriptive statistical analysis and correlation and logistic regression analysis were done using SPSS v.21 and R3.1. Efavirenz showed a weak positive linear relationship with endogenous progesterone at efavirenz concentrations below 12μg/ml. Based on serum endogenous progesterone, the observed hormonal contraceptives failure rate (24.5%) was higher than expected (maximum 8%). A higher proportion of HIV positive women on efavirenz based HAART (26.5%) was at risk of contraceptive failure than their HIV infected HAART naïve counterparts (20%) though it was not statistically significant (p= 0.63). Efavirenz mid‐dose plasma concentrations seem to have no significant effect on mid‐luteal endogenous progesterone concentrations and contraceptive outcomes among HIV infected Ugandan women coadministering ethinylestradiol/levonorgestrel oral pills.